GSK (NYSE:GSK) Issues FY 2024 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.120-2.160 for the period, compared to the consensus estimate of 3.960. The company issued revenue guidance of $41.2 billion-$41.2 billion, compared to the consensus revenue estimate of $39.6 billion.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Citigroup raised shares of GSK from a neutral rating to a buy rating in a report on Tuesday, February 13th. Morgan Stanley started coverage on GSK in a report on Tuesday, January 23rd. They set an equal weight rating for the company. Finally, Guggenheim upgraded shares of GSK from a neutral rating to a buy rating in a report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of Moderate Buy.

GSK Stock Performance

Shares of NYSE GSK traded up $0.15 during midday trading on Friday, reaching $43.50. The company’s stock had a trading volume of 4,048,068 shares, compared to its average volume of 3,498,257. The stock has a market capitalization of $90.15 billion, a P/E ratio of 15.76, a PEG ratio of 1.49 and a beta of 0.65. The firm has a 50 day moving average price of $41.87 and a 200-day moving average price of $39.14. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.62. GSK has a 12-month low of $33.33 and a 12-month high of $43.84.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). The company had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. As a group, equities analysts predict that GSK will post 4.13 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This represents a $1.50 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend is Thursday, May 16th. This is a boost from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is currently 57.61%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.